ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pouard, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pouard, P.

Ann Thorac Surg 1998;65:S40-S44
© 1998 The Society of Thoracic Surgeons

Review of Efficacy Parameters

Philippe Pouard, MDa

a Hôpital Laënnec, Paris, France

Address reprint requests to Dr Pouard, Hôpital Laënnec, Assistance Publique-Hôpitaux de Paris, 42 rue de Sèvres, 75007 Paris, France

Presented at Risk Assessment of Major Perioperative Issues in Pediatric Cardiac Surgery, Washington, DC, May 7, 1997.

Background. The deleterious effects of cardiopulmonary bypass are greater in pediatric patients than in adults. The use of aprotinin to manipulate hemostasis has become an important factor in attempts to reduce adverse consequences of these effects.

Methods. This article reviews the literature on the use of aprotinin in pediatric cardiac surgery.

Results. Available studies have many deficiencies, often including lack of placebo control, nonhomogeneous populations and procedures, and absence of information on aprotinin plasma concentrations. Comparison of trial results is further complicated by differences in dose regimens, heparin-protamine protocols, and priming.

Conclusions. Further trials are required to adequately assess aprotinin effect on platelet preservation, particularly in neonates, to evaluate aprotinin’s antiinflammatory action, and to determine optimum dosages to achieve specific objectives. Aprotinin in pediatric cardiac surgery has been found to be associated with no adverse effects, to decrease fibrinolytic and probably platelet activation, and to offer important clinical benefits in specific groups of patients.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
C. Murugesan, S. K. Banakal, R. Garg, S. Keshavamurthy, and K. Muralidhar
The Efficacy of Aprotinin in Arterial Switch Operations in Infants
Anesth. Analg., September 1, 2008; 107(3): 783 - 787.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
E. B. Mossad, S. Machado, and J. Apostolakis
Bleeding following deep hypothermia and circulatory arrest in children.
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 34 - 46.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. M. McCall, M. M. Blackwell, J. T. Smyre, J. J. Sistino, J. R. Acsell, B. H. Dorman, and S. M. Bradley
Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial
Ann. Thorac. Surg., March 1, 2004; 77(3): 983 - 987.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
G. D. Williams, S. L. Bratton, and C. Ramamoorthy
Factors Associated with Blood Loss and Blood Product Transfusions: A Multivariate Analysis in Children After Open-Heart Surgery
Anesth. Analg., July 1, 1999; 89(1): 57 - 57.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.